Korea Biobank Network
detail content area
Pusan National University Hospital
Established in 1956, Pusan NUH has been providing medical services for over half a century. It is a large-scale, high-grade general hospital with over 2,300 beds and 3,900 employees. It is also a leader in the Southeast Asian medical industry, playing a major role in improving the health of the nation and advancing local medicine. The hospital has a large number of accomplishments, including the opening of the Pusan Cancer Center in 2009, receiving recognition from the Ministry of Health and Welfare in 2011, a second-place selection for “brand power” among general hospitals in 2012, and the highest grade in the Public Health and Medical Business Assessment in 2013. The hospital has increased its competitiveness and contributes to the development of the medical industry not only through patient treatment but also through persistent research activities involving the operation of six major national designated centers.
The objectives of the Pusan NUH Biobank are to acquire and distribute various high-quality human bioresources and to implement personalized medicine. The Biobank aims to become a specialized bank for the personalized diagnosis and treatment of colon cancer and cardiovascular diseases. The Pusan NUH Biobank is committed to the formation of the foundation of the national bio industry through the efficient collection and distribution of human bioresources.
- December 2007: Composition of the Pusan NUH BiobankTF Team
- March 2008: Selection as a Regional Biobank
- Granted permission to open a gene bank
- May 2008: Establishment of the Pusan NUH Biobank operating regulations and supervising board
- August 2008: Introduction of the Pusan NUH Biobank apparatus and installation of the computerized data system
- June 2009: Opening ceremony for the Pusan NUH Biobank
- November 2009: Opening ceremony for the Yangsan Pusan NUH Biobank
- January 2013: Selection for Phase 2 as a Regional Biobank
- December 2014: Selection, on the commendation of the Minister of Health and Welfare, as an outstanding organization
within the KBP
- January 2016: Progression to Phase 3 of the Korea Biobank Project
Status of Human bioresources
The Pusan NUH Biobank is actively collecting various human bioresources for a total of 71 diseases, including cardiovascular disease, and colon cancer, and is currently in possession of 556,488 vials of human bioresources from 44,563 individuals (blood: 4,542; serum: 197,086; mononuclear cell: 34,623; fresh frozen normal tissue, fresh frozen tumor tissue: 79,702; urine: 2,579; ascites: 393; cerebrospinal fluid: 93; sputum: 181; bile: 2,502). The Biobank intends to provide high-quality data to researchers while concurrently acquiring human bioresources with high added value.
Projects and Distribution Results
The Biobank is widely introduced to the public; collection is being promoted through various methods, including the distribution of publicity brochures aimed at patients and visitors to the hospital, a publicity video played in the hospital lobby, and the airing of talks that explain the role of the Biobank. Pusan NUH has advertised the Biobank, announced the status of collected biospecimens for different diseases, and promoted active collection and distribution. These efforts include the hosting of seminars and publication of newsletters (quarterly).Advertising is also being conducted at the Busan Biological Industry Conference, Busan Bio Forum, and Cancer Expo, which target researchers and biobank affiliates from the Busan area, andinuniversity hospitals in the Busan area.
The Pusan NUH Biobank has converted autologously collected resource catalogs, storage information, and clinical information into a database to encourage the panel collection and distribution of high-value human bioresources related to individual diseases and patients.AS such, the collection of human bioresources from a single patient becomes easier. In addition, by utilizing appropriate storage methods for panel collection and distribution, minimizing quantities relating to rare diseases, and maintaining the maximum possible number of vials, the Biobank can afford wide distribution to various researchers. The biobank is conducting its own research to improve quality control methods through the formation of a board that will oversee quality control every quarter. Subsequently, the appropriate quality control standards will be maintained through self-assessment, which is expected to improve product quality.
Biobank, B1F, C Building, Pusan National University Hospital Cancer Center, 179 Gudeok-ro, Seo-gu, Busan, Korea (49241)
- E-mail: firstname.lastname@example.org